

Resource Summary Report

Generated by [NIF](#) on Aug 3, 2026

Mutect2

RRID:SCR_026692

Type: Tool

Proper Citation

Mutect2 (RRID:SCR_026692)

Resource Information

URL: <https://gatk.broadinstitute.org/hc/en-us/articles/360037593851-Mutect2>

Proper Citation: Mutect2 (RRID:SCR_026692)

Description: Software tool to call somatic short mutations via local assembly of haplotypes. Somatic variant caller that uses local assembly and realignment to detect SNVs and indels.

Resource Type: software resource, software application

Defining Citation: [DOI:10.1101/861054](https://doi.org/10.1101/861054)

Keywords: Somatic variant caller, call somatic short mutations, detect SNVs and indels,

Resource Name: Mutect2

Resource ID: SCR_026692

Record Creation Time: 20250401T060330+0000

Record Last Update: 20260801T191346+0000

Ratings and Alerts

No rating or validation information has been found for Mutect2.

No alerts have been found for Mutect2.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1110 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Chow Z, et al. (2026) Colon cancer in Appalachian Kentucky: Unique genetic, microbiome and obesity findings in a cohort comparison. HGG advances, 7(1), 100527.

Miglierina E, et al. (2026) DIS3 licenses B cells for plasma cell differentiation in humans. Cellular & molecular immunology, 23(1), 31.

Kim CY, et al. (2026) Integrative multi-omics of matched primary and liver metastatic colorectal cancer organoids identifies putative molecular targets. Translational oncology, 63, 102592.

Pan R, et al. (2026) Basement membrane-associated gene P3H2 regulates osteosarcoma progression and epithelial-mesenchymal transition through AKT/mTOR signaling axis. Translational oncology, 63, 102569.

Liu Y, et al. (2025) SpatialSNV: A novel method for identifying and analyzing spatially resolved SNVs in tumor microenvironments. GigaScience, 14.

Mohammadi M, et al. (2025) Cyclin-dependent kinase 9 inhibitors as oncogene signaling modulators in combination with targeted therapy for the treatment of colorectal cancer. bioRxiv : the preprint server for biology.

van Ravensteijn SG, et al. (2025) Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(17), 3678.

Mack T, et al. (2025) Germline genetics, disease, and exposure to medication influence longitudinal dynamics of clonal hematopoiesis. Haematologica, 110(4), 1010.

Magee D, et al. (2025) Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(13), 2710.

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. Cell reports. Medicine, 6(2), 101929.

Greenwald NF, et al. (2025) Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition. bioRxiv : the preprint server for biology.

Sui Z, et al. (2025) Mesenchymal stromal cells promote the formation of lung cancer organoids via Kindlin-2. Stem cell research & therapy, 16(1), 7.

Liu M, et al. (2025) Sex disparities in the association between rare earth elements exposure and genetic mutation frequencies in lung cancer patients. Scientific reports, 15(1), 2185.

Chen LT, et al. (2025) Nanopore-based consensus sequencing enables accurate multimodal tumor cell-free DNA profiling. *Genome research*, 35(4), 886.

Mascarenhas R, et al. (2025) Detecting somatic variants in purified brain DNA obtained from surgically implanted depth electrodes in epilepsy. *Epilepsia*, 66(4), 1234.

Shitara K, et al. (2025) Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. *Nature medicine*, 31(5), 1519.

Myeong J, et al. (2025) Microbial metabolites control self-renewal and precancerous progression of human cervical stem cells. *Nature communications*, 16(1), 2327.

Zheng Q, et al. (2025) Primary exploration of cell-free DNA in the plasma of patients with parathyroid neoplasms using next-generation sequencing. *Cancer cell international*, 25(1), 86.

Koh KN, et al. (2025) Unraveling the Genetic Landscape of Langerhans Cell Histiocytosis in Korean Patients: Comprehensive Insights from Mutational Profiles and Clinical Correlations. *Cancer research and treatment*, 57(3), 873.

Kang EJ, et al. (2025) Clinical Impact of TP53 Mutations in Patients with Head and Neck Cancer Who Were Treated with Targeted Therapies or Immunotherapy. *Cancer research and treatment*, 57(3), 709.